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medications for the same indication are used concurrently. We
investigated whether concurrent utilization of controller asthma
medications in patients switching therapies differs between con-
troller medication classes and whether it may lead to signiﬁcant
biases in observed patterns of medication possession and inap-
propriate claims for long-term patient adherence. METHODS:
We used MPRs as a proxy measure of adherence to asthma
controller medications. Asthma controller utilization patterns
were investigated using the Pharmetrics Managed Care database
for the period April 2003 to March 2006. Asthma patients who
were exclusively on two of three major controller groups were
identiﬁed: inhaled corticosteroids (ICSs), ﬂuticasone/salmeterol
(FS), and leukotriene modiﬁers (LTMs). MPRs were calculated
for days of concurrent possession (DCPs) between last and ﬁrst
prescription recorded, as well as the proportion of days that were
covered by concurrent controller possession (CCPs). RESULTS:
Overall for the study population (n = 7260), 1328 patients had
prescriptions for LTMs and ICSs; 4871 for LTMs and FS; and
1061 for ICSs and FS. The mean CCPs were highest for persons
reporting prescriptions for both LTMs and FS (0.224). Lowest
CCP was for ICS and FS (0.023). DCP over the 3-year observa-
tion period was highest for persons with LTMs and FS (0.152 or
166 days) and lowest for those with ICSs and FS (0.009 or 10
days). CONCLUSION: The analysis points to a signiﬁcant
number of asthma patients using LTMs concurrently with
another controller medication. This occurs despite the lack of
clinical evidential support for concurrent utilization over an
extended period. Estimates of MPRs for controller therapies
based on prescription counts need to be corrected for concurrent
medication usage to avoid overstating therapy adherence.
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OBJECTIVE: To assess the correlation between health care uti-
lization after diagnosis of chronic obstructive pulmonary disease
(COPD) and controller therapies prescribed during the ﬁrst year
after diagnosis. METHODS: A cohort of 991 patients with initial
diagnosis of COPD between January 1, 2003 and December 31,
2004 were constructed from the Lovelace Patient Database.
Inclusion criteria included: ﬁrst diagnosis of COPD (ICD-9CM
491, 492, or 496), >1 year of pre and post-diagnosis observation,
and >1 pharmacy claim. Ethnicity was estimated using the
GUESS (Generally Useful Ethnicity Search System) program. Use
of controller therapy: ﬂuticasone propionate (FP), salmeterol
(SAL), ipratropium (IPR), ipratropium + albuterol (IPA), and
ﬂuticasone/salmeterol combination (FSC) was calculated for each
patient using Medication Possession Ratios (MPR), the mean
number of prescription ﬁlls in the year following diagnosis. Cor-
relations between controller therapy and albuterol use, outpa-
tient, and inpatient visits were assessed using Pearson correlation
coefﬁcients and Negative Binomial regression models controlling
for age, sex, and Hispanic ethnicity. RESULTS: The sample of
991 patients included 6.6% FP, 8.8% IPA, 3.6% IPR, 2.5% SAL,
8.1% FSC, and 77.5% non-controller. The sample was 51.9%
female, 24.9% estimated Hispanic ethnicity, and mean age was
68 years. Albuterol MPR was correlated with FP (r = 0.42,
p < 0.0001), IPA (r = 0.08, p = 0.007), IPR (r = 0.37, p <
0.0001), SAL (r = 0.12, p < 0.0001), and FSC (r = 0.33, p <
0.0001). No controllers were signiﬁcantly correlated with
outpatient visit use. No controllers were signiﬁcantly correlated
with albuterol MPR when controlling for sex, ethnicity, and
age. FSC MPR was the only controller that was negatively cor-
related with hospitalizations (-2.05, p = 0.04). CONCLUSION:
Patients with an initial diagnosis of COPD experienced less hos-
pitalizations with more FSC use during the ﬁrst year, suggesting
a duration-response relationship. Controller use was not signiﬁ-
cantly correlated with albuterol MPR or count of outpatient
visits after adjustment.
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OBJECTIVE: The 2007 Canadian Respiratory Disease Guide-
lines recommend that treatment be initiated with inhaled corti-
costeroids (ICS). An analysis of provincial drug claims data was
undertaken to determine the impact of Ontario’s restricted drug
access system relative to Alberta’s open public formulary on the
use of four types of medication to treat respiratory disease. These
consisted of low cost ICS and higher cost long-acting b2 agonists
(LABA), combination therapy ICS plus LABA (COMBO) and
leukotrienes (LTRA). METHODS: A retrospective 12-month
review of patients aged < 55 years who were treated under the
public and private payer systems in Ontario and Alberta were
analyzed for “ﬁrst use” of inhaled respiratory therapies. “First
use” was deﬁned as a patient who had no prior record in the
previous three years of any controller agent. Inter and intra
provincial utilization comparisons were undertaken and reported
as likelihood ratios (LR). RESULTS: Under the restricted Ontario
public formulary, ﬁrst use ICS was signiﬁcantly more likely over
LABA, COMBO and LTRA (LR = 1.9; 3.0 and 16.9: p < 0.001)
relative to private drug plans in the province. In contrast, there
was signiﬁcantly less ICS use over the more costly LABA in the
open Alberta public system (LR = 0.37; p < 0.001). Furthermore,
there was almost identical usage of ICS vs. COMBO and LTRA
between the Alberta public and private drug plans (LR = 0.91;
p = 0.057 and 1.56; p = 0.001). CONCLUSION: Formulary
restrictions that are in keeping with clinical practice guidelines
appear to be an effective method for promoting appropriate drug
use and containing formulary expenditures. However, the impact
of such restrictions on other health care resources such as hos-
pital admissions for poorly controlled respiratory disease is
unknown. Patient level research is needed to evaluate the total
impact of formulary restrictions on all aspects of the health care
system.
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OBJECTIVE: Despite the recommendations from national guide-
lines, under-use of controller medications and overuse of quick
relief medications persists amongst asthmatics. The main objec-
tive of this study was to determine the effects of health insurance,
prescription drug insurance and availability of peak ﬂow meter
on controller drug therapy not being used by asthmatic patients.
METHODS: Data for this study came from 2004 Medical
Expenditure Panel Survey (MEPS).Study population included all
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asthma patients that reported occurrences of at least one asthma
attack in twelve months. Multiple logistic regression was used to
determine what factors are associated with the risk of absent
controller drug therapy despite the frequent use of quick relief
drugs, i.e., zero use of controllers in 12 months despite the use of
3 or more quick relief canisters in three months. RESULTS: A
total of 1164 patients reported at least one asthma attack in past
12 months. Among these patients, 434 (37%) reported no use of
controller drugs despite the frequent use of quick relief canisters.
The patients that did not have peak ﬂow meter at home were
more likely to report no use of controller drugs despite the
frequent use of quick relief drugs (OR = 1.93; 95% CI:1.92,
1.93). Health insurance (OR = 1.44; 95% CI: 1.43, 1.45) and
prescription drug beneﬁts (OR = 1.21; 95% CI: 1.21, 1.21) also
increased the risk of absent controller drug therapy. CONCLU-
SION: Having peak ﬂow meter increased the likelihood of con-
troller drug use indicating the usefulness of peak ﬂow meter in
asthma treatment and management. Health insurance and pre-
scription drug beneﬁt improved the likelihood of using controller
drugs because of improved access. In order to improve the con-
troller drug utilization amongst asthma patients, attention
should be focused on patients lacking health insurance, prescrip-
tion drug beneﬁts and peak ﬂow meters.
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OBJECTIVE: Rational treatment of bronchial asthma is a
serious problem in developing countries mainly because of access
to medicines. This paper reports the availability and price of two
inhalers in different states of India. METHODS: The data col-
lected for essential medicines at ﬁve sites utilizing a standardized
methodology on medicine prices and availability was used to
collate data for secondary analysis. The surveys were conducted
in public (20–60) and private (20–60) facilities. Anti-asthma
medicines, beclomethasone (50mg/dose) and salbutamol (0.1 mg/
dose) inhalers represented both as innovator brand (IB) and
generic equivalent, were included in the analysis. Medicine prices
were expressed as median price ratio (MPR) to an international
reference price. The surveys were conducted in four states,
Haryana, Karnataka, Maharashtra, Rajasthan and Chennai,
capital TamilNadu, state. Surveys were conducted from
October–December 2004 except Rajasthan survey (April-June
2003). RESULTS: Public sector: Availability—Generic version of
both the inhalers was found only in the Rajasthan state. Avail-
ability of beclomethasone inhaler was 25% and 30% for salb-
utamol. Procurement price –Beclomethasone inhaler was 0.74
and salbutamol inhaler was 0.56 times the international refer-
ence price. Private sector: Availability—Beclomethasone inhaler
was available as innovator brand (55%) and generic version
(90%) in Chennai. In other states only generic version was
available, in the range of 10% to 65%. Salbutamol inhaler
was available in all states and in both the versions, availability
ranging between 20%–95% as innovator brand and 83 -100%
as generic equivalent. Price—MPR for generic beclomethasone
was in the range of 0.87–1.49 at all sites, IB was available in
Chennai and the MPR was 1.08. MPRs for IB and generic
salbutamol range between 0.86–1.12 and 0.82–0.96 respec-
tively. CONCLUSION: Policy interventions are required to
improve access of affordable essential asthma medicines. Asthma
needs to be recognized as a health priority chronic disease in
India.
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OBJECTIVE: To gather information from managed care orga-
nization (MCO) decision makers and employers about asthma
burden, evidentiary requirements, and product attributes that
may inﬂuence formulary decision making for an emerging once-
daily ICS asthma therapy. METHODS: Telephone interviews
were conducted among 10 MCO decision makers and 8
employers representing more than 51 million covered lives.
Research focused on asthma burden, disease management strat-
egies, and formulary decision making. Mean ratings on a scale
from 1 (no effect; not at all important) to 10 (very large effect;
very important). RESULTS: Both MCOs and employers recog-
nized the prevalence of asthma and challenges associated with
management, including patient compliance with ICS. MCOs
reported the economic impact of asthma was most notable in
terms of hospitalizations (7.3), emergency department visits
(7.2), and pharmaceutical costs (7.0). Employers identiﬁed
burden of illness with employee absenteeism (6.0), presenteeism
(5.3), workplace productivity (5.4), and employer health care
costs stemming from both employee asthma and dependent
children with asthma (5.3). ICS product efﬁcacy, safety, com-
pliance, and cost-effectiveness/value were the most important
product attributes driving formulary decision making among
MCOs. Both MCOs and employers had a favorable overall
opinion of the product (6.9 and 6.8, respectively) and felt that
compliance (8.4 and 8.9, respectively) would have a consider-
able impact on decision making. Majority of MCOs (7 of 10)
reported once-daily dosing to be the most important product
attribute (6.9). MCO interviewees emphasized that the product
will need to be priced competitively to secure favorable posi-
tioning in a crowded ICS market. Post-launch evidentiary
requirements may include the need for “real world” head-to-
head comparative effectiveness studies. CONCLUSION: Efﬁ-
cacy, safety, compliance, and cost are primary factors driving
formulary decision making when evaluating emerging ICS
asthma therapies in a crowded market. MCO and employer
organizations have similar priorities with respect to asthma
management and formulary decision making.
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OBJECTIVE: Recent estimates of cost of asthma among chil-
dren in the USA are not available. The objective of this study
was to estimate the incremental direct medical expenditures of
treating asthma among children in the USA. METHODS:
Retrospective analysis was conducted using the 2004 Medical
Expenditure Panel Survey (MEPS) data. Asthmatic children
(age < 18 years; n = 968) were identiﬁed as those with Interna-
tional Classiﬁcation of Diseases (ICD)-9 diagnosis codes for
asthma or those that had a self-report of having asthma in
2004. Separate regression models were developed for total
expenditures and expenditures for various categories of resource
use adjusting for age, gender, race, ethnicity, education, geo-
graphic region, insurance status and number of medications
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